For example, the TLR4 antagonist EB05 was designed to block the interaction between TLR4 on the innate immune cells and the DAMPs produced by viral-mediated cell damage, such as S100A8/A9, HMGB1, and oxidized phospholipids, and to ameliorate the cytokine storm and acute respiratory distress syndrome induced by COVID-19 (Table 2). The gene discussed is TLR4; the disease is acute respiratory distress syndrome.